2 completed, 2 unknown, 1 not yet recruiting, 1 recruiting. 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Unknown 2, Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Proton pump inhibitor: new trials by email Literature Review of Proton pump inhibitor trials Research Report on Proton pump inhibitor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy Experimental (Health Canada Approved Proton Pump Inhibitors) - Primary Lung Cancer, Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 58 | 2025-10-02 | 2025-07-22 |
| Preoperative Use of Pantoprazole for Prevention of Post Operative Nausea and Vomiting in Gynecologic Surgery pantoprazole, Placebo - Postoperative Nausea and Vomiting | Phase 2 | Recruiting | United States Naval Medical Center, Portsmouth | 132 | 2022-08-26 | 2025-05-21 |
| IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity IRX-2, Cyclophosphamide, Indomethacin - Squamous Cell Carcinoma of the Oral Cavity | Phase 2 | Completed | Brooklyn ImmunoTherapeutics, LLC | 105 | 2016-01-11 | 2024-01-30 |
| Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402) General condition, Blood pressure, Patient Reported Outcome - Rectal Cancer | Phase 2 | Unknown | Clinical Research Support Center Kyush | 74 | 2014-10-01 | 2014-11-13 |
| A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2 - Gastroesophageal Reflux Disease | Phase 2 | Completed | XenoPort, Inc. | 460 | 2009-09-01 | 2021-02-21 |
| Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation Proton pump inhibitor - Hearing Loss | Phase 2 / Phase 3 | Unknown | National Taiwan University Hospital | 120 | 2006-08-01 | 2008-11-11 |
Carcinoma, Non-Small-Cell Lung (1) · Fatigue (1) · Gastroesophageal Reflux (1) · Head and Neck Neoplasms (1) · Hearing Loss (1) · Lung Neoplasms (1) · Neoplasms (1) · Postoperative Nausea and Vomiting (1) · Rectal Neoplasms (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Brooklyn ImmunoTherapeutics, LLC (1) · Clinical Research Support Center Kyush (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · National Taiwan University Hospital (1) · United States Naval Medical Center, Portsmouth (1) · XenoPort, Inc. (1)
Canada (3) · United States (3) · Brazil (1) · Japan (1) · Taiwan (1) · United Kingdom (1)
Casey Timmerman, DO (1) · Chen-Chi Wu, MD (1) · Chuan-Jen Hsu, MD (1) · Gregory T Wolf, MD, FACS (1) · Yasunori Emi, MD, PhD (1)